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Abstract
Despite the tremendous advances in the understanding of the molecular mechanisms 
and the complexity of the diseases is one of the present challenges for the scientific com-
munity; then, novel strategies are required to be designed and developed for effective 
strategies for early diagnosis and treatment. As many cellular alterations are observed at 
protein level, high-throughput assays are dramatically needed for biomarker discovery. 
Herein, we describe advantages and limitations of protein microarrays, as proteomics 
strategy useful for multiplex and high-throughput protein characterization in clinical 
samples. Finally, a few examples are discussed; mostly of them related to currently dis-
ease biomarkers already identified in proximal fluids by protein arrays are discussed.
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1. Introduction
Despite the tremendous advances in the understanding of the molecular basis of diseases 
(such as cancer, Alzheimer, genetic diseases), there are some crucial gaps that difficult us 
to understand disease pathogenesis and develop effective strategies for early diagnosis and 
treatment [1].
The current interest in protein microarrays due, mostly in part, to the prospects that pro-
teomics assays, based on them, allow: deciphering the altered protein expression in different 
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levels (tissue, cells, subcellular structures, body fluids, protein complexes,…); the develop-
ment of novel biomarkers for diagnosis or early detection of diseases; the identification of 
new targets for therapeutics; and accelerating drug development through more effective strat-
egies to evaluate therapeutic effect and toxicity [1].
Mainly based on the proteome alterations in disease may occur in many different ways that 
are not predictable from genomics analysis, and it is clear that a better understanding from 
genomic analysis together with an substantial impact in biomedicine.
Recently, there is a large amount of protein microarray approaches available for applications 
related to disease because the employment of these technologies is very useful for better diag-
nostics and to shorten the path for developing effective therapy. In general, protein micro-
arrays allow to increase sensitivity, reduce sample requirement, increase high-throughput 
and identify protein alterations (quantitative and qualitative), such as post-translational 
modifications.
If we want to quantify thousands of proteins in a small number of samples, a typical pro-
teomics discovery experiment employs a non-targeted approach (shot-gun proteomics). The 
hundreds of proteins that result from the comparative analysis, are differentially expressed 
between healthy and diseased samples. After discovery phase, the potential biomarkers pro-
teins are reduced by performing studies on additional patients or at more time points, and/
or by using another technique. Then, these potential biomarkers are verified on a set of 10–50 
clinical samples. In the final step, a small number of biomarkers is “validated” on 100–500 
clinical samples. Bearing in mind this conventional biomarker workflow, high-throughput 
assays are required in order to overcome the gap between translational research and clinical 
needs (from bench to the bedside) [1] (Figure 1).
Figure 1. Stages in the development of a biomarker.
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Biomarkers or biological markers are defined as measurable characteristics that indicate the 
state of a biological process, differentiating if it is normal or pathological. They are all those 
molecules that are found in body fluids in low abundance and that are associated with spe-
cific health or disease processes [2]. The methodology to establish that a biomarker is good for 
clinical application is divided into three steps: discovery, verification and validation as it has 
been said before [3, 4].
Proteomics, the scientific discipline that studies proteins, has identified several proteins that 
can act as biomarkers. There are several techniques that use biomarkers and that allow an 
early diagnosis of the disease. These include new generation sequencing, mass spectrometry 
and protein arrays [5, 6]. In this chapter we will focus on the study of arrays.
Microarray technology is a term that refers to the miniaturization of thousands of assays in a 
single device, allowing the simultaneous and massive analysis of a large number of biomol-
ecules in a single biological sample. They allow the study of a large number of parameters in a 
single test with a minimum requirement of sample and reagents, which is why they constitute 
a simple, fast and very sensitive sampling technique [7, 8].
The microarrays present several innovative strategies for their applications such as the iden-
tification of biomarkers and the interactions between proteins that may help in the future to 
routine clinical analysis.
There is a great variety of arrays which can be classified according to their content in protein 
microarrays, functional protein arrays and reverse phase arrays; according to their shape in 
planes and spheres; and also according to their detection method.
In this chapter we will explain all these types of arrays, some of their applications in bio-
marker discovery as well as validation/verification.
1.1. Biomarkers discovery
A biomarker is defined by the Food and Drug Administration (FDA) as “A characteristic that 
is objectively measured and evaluated as an indicator of normal biological processes, patho-
genic processes, or pharmacological responses to a therapeutic intervention.”
It is possible to distinguished three categories depending on the application of the biomarker: 
diagnostic biomarkers used for disease detection, prognostic biomarkers used for predict the 
course of a particular disease such as, recurrence, progression, and survival and predictive 
biomarkers used for predict the response to treatment that could be subsequently applied in 
patient assessment [1].
During last years, biomarker research and its translation into the clinics have been accelerated 
by protein microarrays due to the extraordinary capacity for identifying of valuable biomark-
ers in a short period of time without the requirement of any prior in-depth knowledge into the 
mechanism of disease progression.
Moreover, protein microarrays are reliable for analyzing targeted/non-targeted biomarkers 
presented in mostly of human proximal body fluids (such as plasma, serum, synovial liquid,…) 
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with a wide dynamic range. In contrast with other proteomic strategies, protein microarrays 
avoid the sample pre-fractionation. Thus, for example, serum, plasma, urine and tissue extracts 
which are complex and non-fractionated proteome mixtures, could be used for experimenta-
tion. For this reason, among others, protein microarrays offer a powerful technology for func-
tional proteomics analysis in HT format.
Microarray technologies, like DNA arrays, printed dense spots of capture ligands immobi-
lized onto a solid support that are exposed to samples containing corresponding binding 
molecules (often called queries), allowing the simultaneous analysis of thousands of capture 
targets within the same assay. Ekins and collaborators described these binding events based 
on miniaturization as the key parameter. They predict that a system that uses small amounts 
of capture molecules and a small amount of sample could be more sensitive than a system 
using a hundred times more material. In fact, this is the case when K < 0.1 (where K is the 
affinity constant between ligand and target) [9].
The capture ligand is presented in a confined area of array, reducing its diffusion. The spe-
cific binding event with its target takes place with the highest signal intensities and optimal 
signal-to-noise ratio could be achieve in these small spots [9] (Figure 2). An immunoassay 
Figure 2. Process of microarray technology.
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in an array format displays sensitivities in the pM to fM range, enabling test low-abundant 
(pg/mL) analytes in crude proteomes with a small volume of sample. In many cases, protein 
microarrays show a relevant advantage in clinical applications because the samples to test are 
minimal [10].
For that reason, protein array technology needs to use a multiplex and highly sensitive 
protein assay capable of handling and resolving complex proteomes with limited available 
sample [10].
Recently, several types of protein microarrays have been developed and applied as multiplex 
throughput assay in several biological characterization. Here, it is described the principal 
features of protein microarrays.
2. Description of protein microarrays
In general, protein microarrays are classified according to features such as content, format, 
detection method and according to final application such as analytical and/or functional. 
Here, it is described the main aspects of the different types of protein microarrays.
2.1. Arrays according to their nature of the capturing agent
In general, there are three types of arrays according to their content:
2.1.1. Analytical protein microarrays or antibody microarrays
In these arrays, antibodies are printed onto array surface and used multiplexed affinity 
reagents to detect and quantify proteins in complex biological samples [8, 11].
It is based on the antibody antigen interaction. Antibodies have the ability to bind to a very 
specific protein, so particular or rare analytes can be detected in highly heterogeneous mix-
tures. They are usually used to identify biomarkers which predict a biological condition such 
as healthy or pathologic.
So many studies have shown that only a fraction of antibodies may properly work and this may 
be due to the loss of antibody activity by degradation or denaturation on storage or during the 
printing process, or due to inappropriate antibody orientation onto the array surface [7].
2.1.2. Functional protein arrays or recombinant protein arrays
It is based in the identification of protein interactions with different molecules (proteins, 
DNA, lipids, drug, etc.), so recombinant proteins are printed onto array surface.
Some examples are protein in situ array (PISA), printing arrays from DNA (DAPA) nucleic 
acid programmable protein array (NAPPA) and multiplexed nucleic acid programmable pro-
tein array (M-NAPPA). They are essential for pharmaceutical industry because they allow to 
know protein interactions [11].
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PISA is based on DNA amplified by PCR as a template. The DNA that encode the protein of 
interest contains a T7 promoter or another strong transcriptional promoter and an in-frame 
N-12 or C-terminal tag sequence for protein capture onto the surface. PISA offers the pos-
sibility to cell-free production of protein arrays. It means protein are produced using cell 
extracts directly on the surface os arrays. PISA demonstrated that multiple proteins could be 
produced without the need of using cells for expression followed by lysis and purification to 
make the proteins [11].
DAPA is a technique derived from PISA, but DAPA allows use the same DNA template slide 
repeatedly for printing up to 20 copies of the same protein and also DNA could be reused 
after prolonged periods of time. DAPA takes a long time to express proteins due to the diffu-
sion of proteins through the membrane. This technique starts by spotting the PCR amplified 
DNA fragments encoding the tagged protein on one slide. This slide is sandwiched with 
another Ni-NTA slide where a tag-capturing agent immobilizes the expressed protein. A per-
meable membrane with the cell-free lysate which allows coupled transcription and transla-
tion is places between the two slides. Then, the expressed proteins are captured to the surface 
on the other slide through the capture ligand. Overall, DAPPA requires long time to express 
proteins and this technique presents the protein diffusion as strong limitation, in particular 
with large proteins [7, 9, 11, 12].
NAPPA uses cDNA templates cloned into expression plasmids which adds a transcrip-
tional promoter and also an in-frame polypeptide capture tag. It has several advantages: 
(1) once the clone is produced as a glycerol stock it becomes an indefinitely renewable 
resource that could be shared with other labs; (2) if the clone is carefully sequence verified, 
then the resource will have long-term sequence fidelity; (3) the use of plasmids removes 
some of the length constraints on the epitope tags, so that functional protein tags can be 
used. There are many applications of NAPPA where the proteins are fused with gluta-
thione-S-transferase (GST); nevertheless, other tags such as flag, HA, c-myc, and Halo 
tag have been used in specific applications. High quality supercoiled plasmid DNA is 
purified from bacteria cultures and printed onto an activated ester surface along with a 
homo-bifunctional crosslinker, bovine serum albumin (BSA) and anti-GST antibody. BSA 
efficiently increased the DNA binding and narrows down the unspecific interactions and 
anti-GST attaches the protein expressed. When cell-free expression system is added to the 
array, a coupled transcription/translation reaction is produced and the nascent protein is 
linked to the capture agent tag the C-terminal end assuring the complete translation of the 
protein [10, 11, 13].
Puromycin capture protein arrays (PuCA) are cell-free expression protein arrays based on the 
affinity of puromycin by expressed peptide/protein. First, PCR DNA is transcribed to mRNA, 
and a single-stranded DNA oligonucleotide modified with biotin and puromycin on each end 
is then hybridized to the 3′-end of the mRNA. The mRNAs are placed on a slide and immo-
bilized by the binding of biotin to streptavidin which is previously coated on the slide. Cell 
extract is then dispensed on the slide for in situ translation to take place. When the ribosome 
reaches the hybridized oligonucleotide, it stops and incorporates the puromycin molecule to 
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the nascent polypeptide chain, thereby attaching the newly synthesized protein to the micro-
array through the DNA oligonucleotide [14].
M-NAPPA is based on combining up to five different DNA plasmids at one point. This 
increases the number of proteins displayed by microarrays by five. It also reduces the cost and 
the time spent in work. M-NAPPA would be useful in unbiased HT screening studies, such 
as protein-protein interactions, protein-DNA interactions, discovery of drug binding target as 
well as (auto)antibody biomarkers for a variety of human diseases [15].
2.1.3. Reverse phase protein arrays
In these arrays, biological samples, tissues and cell lysates are printed onto array surface. 
The detection is accomplished by antibodies link with specific proteins, and then link 
with another antibody with fluorescence. They offers the potential for rapid comparison 
of the levels of such proteins present among a significant number of samples on a single 
array [7, 8].
The problem is the interaction of the lysate matrix, therefore validated antibodies should 
demonstrate no cross-reactivity toward other biomolecules of the lysate (Figure 3).
Figure 3. Arrays according to their nature of the capturing agent.
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3. Arrays according to the format
3.1. Planar arrays
Planar arrays are based on high-density microspots of ligand deposited onto a solid support 
and separated by a minimal distance. It is necessary to know some parameters that influence 
in the assay performance like spot size and morphology, ligand capacity, background signal, 
limit of detection and spot reproducibility [13].
3.2. Microsphere arrays
Microsphere arrays are based on the simultaneous use of different populations of micro-
spheres labeled with several fluorochromes. Each one is covered by different antibodies in 
order to incubate a biological sample of interest [7].
4. Arrays according to their detection method
Depending on the detection method it is classified in methods based on labels and free-label 
methods [7].
4.1. Methods based on labeling
4.1.1. Conventional fluorescent labels
Among them are radioisotopes and conventional fluorochromes like fluorescein, BODIPY or 
cyanins. Cyanines are the most used in protein arrays due to its minimal interaction with 
other biomolecules and its high intensity. More than two fluorochromes can be combined to 
identify several biomarkers at the same time. It is used for cancer biomarkers.
4.1.2. Flow cytometry sphere arrays
Flow cytometry can be used to detect soluble proteins present in body fluids or in cell lysates 
using microspheres. The CF has two lasers for the analysis quantitative and qualitative that 
allows to know the binding of target proteins with the microspheres. Comparing conven-
tional fluorescent techniques, flow cytometry allows rapid and accurate quantitative-qualita-
tive evaluation of a high number of proteins, with low cost and high sensitivity.
4.1.3. Magnetic spheres
These systems are an union of magnetic spheres with antibodies that allow the detection of 
proteins. They capture soluble proteins with high reproducibility and sensitivity, associated 
with low background noise, a wide dynamic range and low cost.
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4.1.4. Quantum dots as fluorescence labels
The “Quantum dots” (QDs) are nano-crystals, formed by a core of semiconductor and fluo-
rescent material coated with another semiconductor, which have very stable optical proper-
ties and a large gap between the wavelengths of emission and excitation of the complement. 
These nanometric particles could work like labels joining with peptides or antibodies for the 
recognition of cellular components. They have a high fluorescence, greater photo-stability, 
multicolored excitation, an adjustable and narrow emission spectrum, and their higher quan-
tum yield, compared with organic fluorochromes. They also have several disadvantages like 
its high susceptibility to oxidation and photolysis as well as some risks for human health and 
the environment. They are used to localize tumor biomarkers.
4.1.5. Metal NPs as a label
Gold nanoparticles are used in protein arrays due to their optical properties, quantum effi-
ciency and compatibility with a wide range of wavelengths.
4.2. Free-label methods
4.2.1. Surface plasmon resonance (SPR)
This technology is based on the generation of plasmons on a surface, which are oscillations 
of free electrons propagated parallel to the metal/medium interface, which allows to mea-
sure the changes in the refractive index of the sensor surface. The intensity variation of the 
reflected light and/or the angle of incidence tell us if there are molecular associations or dis-
sociations, allowing to determine the relationship between the association and dissociation of 
biomolecules with each other. In addition, the SPR technology also allows evaluate the affin-
ity and specificity of these interactions, facilitating the measurement of biomolecular interac-
tions in real time with high sensitivity.
4.2.2. Microcantilevers
Microcantilevers are thin sheets of silicon coated with a gold surface associated with nanome-
chanical systems of biomolecular recognition. For this reason, the antibodies or proteins are 
immobilized on said sheets, so that when there is an interaction between these molecules and 
their possible ligands we can measure the variation in the position of the sheet using different 
optical or electronic systems.
4.2.3. Atomic force microscopy (AFM)
It is a microscopic analysis observing only the topological variations of the surface of an object. 
It has been used for the evaluation of the immobilization of biomolecules with a micrometric 
resolution, and for the detection of protein interactions on the arrays surface.
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5. Arrays according to the applications
Bearing in mind the final application, protein microarrays are classified into two categories: 
Analytical arrays and functional arrays.
5.1. Analytical arrays
These arrays are normally used to quantitatively identify the presence of multiples protein 
in one single assay. Commonly, the main application is the detection of differently expressed 
proteins and their abundance in different samples. Biomarkers are determined by this type of 
arrays. They are biometric measurements, including molecular signatures, that predict a bio-
logical or clinical condition for example, normal or pathologic, often with potential diagnostic 
or prognostic value [9, 10, 16].
5.2. Functional protein arrays
These arrays are mainly used for the characterization and identification the specific function 
of proteins, as well as their interactions with other molecules (including proteins, peptides, 
small molecules/drug, enzyme/substrates or nucleic acids,…) [12, 17]. Moreover, functional 
protein arrays also allow the detection and identification of post-translational modifications 
(PTMs), such as glycosylation, phosphorylation, acetylation,… which typically modulate the 
proteins’ function, regulation and/or turnover.
Table 1. Advantages and limitations of protein microarrays in biomedicine.
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Refers to research, functional protein arrays present the detection of multiple protein inter-
actions with low reagent consumption in a fast and low cost fashion. On the translational 
side, the discovery of these interactions will promote the progress of new pharmaceutical 
targets, diagnostics and therapeutics. As a consequence, this technology is very interesting in 
the pharmaceutical industry [10] (Table 1).
6. Multiplex biomarker detection by protein microarray assays
During last decade, protein microarrays have been successfully employed in multiplex detec-
tion for biomarker discovery; here, it is remarked a few of these studies in order to illustrate 
the utility of these approaches in the field.
6.1. Oncology diseases-specific biomarkers
Haab et al. defined a panel of five serum proteins significantly expressed in serum between 
prostate cancer patients (33) and 20 controls [18]. In addition, this team has also identified 84 
proteins with differentially relative abundance between diagnosed lung cancer patients and 
healthy controls [19].
In a similar approach, Wittekind and colleagues reported a set of proteins as biomarker can-
didates associated with hepatocellular carcinoma [20]. Nowadays, several studies have been 
performed and focused on biomarker identification in several oncological pathologies; for 
example: In ovarian cancer, 11 proteins have been identified by Amonkar et al. [21]; Sreekumar 
et al. identified a panel of proteins as biomarker candidates in colon carcinoma cells [22]; Díez 
et al. has identified differentially expressed proteins in B-cell chronic lymphocytic leukemia 
which are related with target therapeutics [23]. Previously, Below and coworkers have devel-
oped an antibody microarray to immunophenotype 1100 leukemia and lymphomas accord-
ing to the abundance of a panel of 82 antigens or cluster of differentiation (CD) characterized 
at the surfaces of lymphocytes [24].
6.2. Vaccine candidates
In 2014, the firstly reported study about pathogen-host protein interactions by CID and work-
ers. In this work, they studied the presence of post-transcriptional modifications in effector 
proteins, T3SS proteins, from different mutants of Salmonella typhimurium when they infected 
in vitro Hela. Lysate collection representing all infection conditions are printed and using sev-
eral validated antibodies, they show a comparative results among the different assays accord-
ing to abundance proteins or post-transcriptional modifications [25].
Another similar study, performed by Li and coworkers, has been published about identifica-
tion of 149 antigens from Yersinia pestis presented in the serum from EV76 rabbit and to test 
the immunogenicity of several viral proteins [26].
In 2009 Thanawastein et al. developed an approached called Expressed protein screen for 
immune activators (EPSIA) which were successfully applied in the identification of novel bac-
terial immunostimulatory proteins from Vibrio cholerae [27].
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Recently, Manzano et al. reported a set of novel vaccine candidates for O. moubata based on a 
systematic characterization of >2000 host-pathogen interactions, which were evaluated with 
self-assembled protein microarrays based on a cDNA library encoding >400 recombinant pro-
teins of O. moubata [28].
In a most recent study, Montor et al. describe a work using NAPPA arrays to evaluate 
candidate membrane antigens in P. aeruginosa which could help to track the immune 
responses of patients infected with P. aeruginosa and healthy ones. In this work, 12 pro-
teins have been identified being mostly of them related with adaptive immune response 
in infected patients [29].
6.3. Auto-immune diseases
In response to many pathological processes, the humoral immune system generates antibod-
ies to self-proteins (“auto-antibodies”). These auto-antibodies are generated due to antigen 
over-expression, mutation, altered post-transcriptional modifications of altered degradation 
released from damaged tissue which lead to their recognition by the immune system. Auto-
antibodies have several benefits which make them as suitable source of biomarkers: (1) They 
have been discovered before the appearance of clinical symptoms; (2) They are simple to 
identify even at low levels once their target antigen is known; (3) they are easy to reunite from 
blood; and (4) they could be show in higher levels and with a longer half-life than their target 
antigens, which may only be present in transiently in blood [10].
For example, NAPPA arrays were used for serological screening for the first time in 2007 by 
Anderson et al. They investigated the presence of antibodies against tumor antigens in breast 
cancer. The tumor-suppressor p53 is well-characterized in several solid tumors and the pres-
ence of antibodies against p53 is mainly due to mutations in its gene which lead to alterations 
in its half-life. By this approach, the authors presented that p53-specific antibody levels were 
significantly lower in healthy donors than in breast cancer patients and the response to p53 anti-
gen was detected in Stage II disease. Also they studied that the antigen sites of p53 with several 
antibodies which recognized distinct epitopes of the protein to confirm that many regions of the 
protein expressed in NAPPA were accessible to antibodies in serum detected to them [10, 30].
In a follow-up work, also this group performed a wide screen for new auto-antibodies in 
breast cancer. They designed and developed 4988 candidate antigens to detect their auto-anti-
bodies in serum samples from breast cancer patients with stage I–III disease. This screening 
was performed in three stage design that entailed comparing cases and controls and eliminat-
ing uninformative antigens at each stage. At the final phase, slightly more than 100 antigens 
were tested and 28 auto-antibodies were identified that distinguished benign breast disease 
from invasive cancer under blinded conditions [10, 30].
With a similar workflow, Labaer et al. developed a pilot NAPPA to assess auto-antibodies 
present in juvenile idiopathic arthritis (JIA) which is a disease characterized by chronic joint 
inflammation in children [31].
Recently, Fuentes’s lab has performed a screening of auto-antibodies in osteoarthritis and arthri-
tis rheumatoid by using NAPPA arrays and validated with other protein arrays technologies [32].
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6.4. Functional biomarkers as drug targets
A decade ago, Labaer and colleagues evaluated functional properties of the proteins IVTT 
expressed onto the array by performing protein-protein interactions in high-throughput for-
mat. In this report, they printed an array expressing 647 unique genes in duplicate and tested 
for several well characterized interacting pairs including Jun-Fos and p53-MDM2 [33].
A more recent study, Manzano et al. published a work where they applied NAPPA to study 
protein interactions. In this study, a novel interactor partners were identified for P-selectin 
and phospholipase A2 and further validated [34].
Recently, a novel functional array, designed by Pascal Braun, identified novel cell signaling path-
ways in Arabidopsis thaliana by evaluating protein interactions onto this NAPPA technology [35].
In addition, a further study has just been published where evaluated multi-protein complex 
in NAPPA format. In this study, four novel tuberculosis-related antigens where identified in 
guinea pigs vaccinated with Bacillus Calmette-Guerin (BCG) and also validated with ELISA [36].
7. Conclusions and further directions
Here, we have briefly reviewed protein microarray field as suitable platform for multiplex 
assays in high-throughput format. Thus, the focus was on two main perspectives: (i) Key 
technological aspects, (ii) Biological Applications.
However, as we described previously, despite the fundamental advances in protein microar-
rays, allowing characterization of whole human proteome is still remaining as a challenge. 
Then, the information provides light on the functions of proteins and genes whose functions 
are currently unknown.
Overall, protein arrays may provide relevant information about the biological function of gene 
products. Although, it is still necessary to develop and optimize some key aspects of protein 
microarray in the future, other proteomics approaches could provide complimentary results.
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